A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

July 5, 2022

Study Completion Date

July 5, 2022

Conditions
Fibromatosis
Interventions
DRUG

Triamcinolone Acetonide

A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT03627741 - A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors | Biotech Hunter | Biotech Hunter